What changed in Eli Lilly And Company's latest annual report
In the year ended 31 Dec 2025, Eli Lilly And Company's revenue rose 44.7% to USD 65.18bn, from USD 45.04bn; net income rose 94.9% to USD 20.64bn, from USD 10.59bn; cash and cash equivalents rose 122.4% to USD 7.27bn, from USD 3.27bn.
Year ended 31 Dec 2025. Source: 10-K filed 12 Feb 2026, read it on SEC EDGAR.
USD 45.04bn to USD 65.18bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 45.04bn | 65.18bn | Up 44.7% |
| Net income | 10.59bn | 20.64bn | Up 94.9% |
| Total assets | 78.72bn | 112.48bn | Up 42.9% |
| Long-term debt | 28.53bn | 40.87bn | Up 43.3% |
| Cash and cash equivalents | 3.27bn | 7.27bn | Up 122.4% |
| Shareholders' equity | 14.27bn | 26.54bn | Up 85.9% |
Questions people ask
Did Eli Lilly And Company's revenue grow last year?
Revenue grew 44.7%, from USD 45.04bn to USD 65.18bn in the year ended 31 Dec 2025.
Is Eli Lilly And Company profitable?
Yes. Net income was USD 20.64bn in the year ended 31 Dec 2025. The year before: USD 10.59bn.
How much cash and debt does Eli Lilly And Company have?
At its latest year end (31 Dec 2025), Eli Lilly And Company reported cash and cash equivalents of USD 7.27bn and long-term debt of USD 40.87bn.
Where do these numbers come from?
From Eli Lilly And Company's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Eli Lilly And Company?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%
- Regeneron Pharmaceuticals, Inc.Cash and cash equivalents up 25.3%